This is the authors' abstract. We don't add key points for this paper.
Five patients with progressive, metastatic Ewing's sarcoma were treated with infusions of mithramycin. Two had excellent regressions of their tumors; one patient has no clinical evidence of tumor more than 7 years after mithramycin was given. Patients who are resistant to cyclophosphamide may respond to mithramycin and vice versa. The exact role of mithramycin in patients with Ewing's sarcoma is not known. Further experimental trials are indicated with mithramycin alone and in combination both as adjunctive therapy and for the treatment of metastatic disease.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Kofman et al. (1973) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: